Press releases
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
- Sage Therapeutics to Present at Upcoming March Investor Conferences
- Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
More ▼
Key statistics
As of last trade SAGE Therapeutics Inc (SG7:DUS) traded at 12.15, 4.20% above its 52-week low of 11.66, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.15 |
---|---|
High | 12.15 |
Low | 12.15 |
Bid | 12.60 |
Offer | 12.66 |
Previous close | 12.22 |
Average volume | 36.11 |
---|---|
Shares outstanding | 60.18m |
Free float | 52.68m |
P/E (TTM) | -- |
Market cap | 788.69m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of May 03 2024 07:10 BST.
More ▼